Comparison of Cognitive and Linguistic Functions among Multiple Sclerosis Patients and Healthy Controls

Document Type : Original Article


1 Department of General Psychology, Azad University of Marvdasht, Marvdasht, Iran

2 Department of Psychology, Shiraz Branch, Islamic Azad University, Shiraz, Iran



Introduction: Multiple Sclerosis (MS) is an incapacitating neurological disease with diverse signs, consisting of difficult or unclear articulation of speech and cognitive and linguistic deficits. The purpose of this study was to compare the cognitive and linguistic functions among MS individuals and healthy controls.
Method: The present descriptive and cross-sectional study was performed at Shahid Motahari Clinic of Shiraz, Iran, in 2018-2019. The participants were selected by using a purposeful sampling method from September 2018 to December 2018, at the MS centers of neurology departments. The Persian aphasia test was used as the research instrument to evaluate the cognitive functions in MS patients. The data were analyzed using the SPSS version 23 software.
Results: The results of the present study revealed that the processing of all subscales, except for transcription, letter and word dictation, and sentence dictation, were significantly different between healthy and unhealthy individuals. Moreover, the results showed that the production of the focused sentence were worse in unhealthy individuals compared to healthy individuals (P < 0.05).
Conclusion: The results of this study showed that patients with MS were involved in linguistic and cognitive problems.  Language and speech therapists who interact with these patients need to be aware of cognitive-linguistic disorders and consider this in their assessment, management, and intervention.


  1. References

    1. Grzegorski TLosy J . Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research.Rev Neurosci. 2017; 27; 28(8):845-860. doi: 10.1515/revneuro-2017-0011.
    2. Guenter WJabłońska JBieliński M, Borkowska A. Neuroimaging and genetic correlates of cognitive dysfunction in multiple sclerosis. Psychiatr Pol. 2015; 49(5):897-910. doi: 10.12740/PP/32182.
    3. Rocca MA, Amato MP, De Stefano N, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015; 14(3):302–17.
    4. Trenova AGSlavov GSManova MGAksentieva JBMiteva LDStanilova SA. Cognitive Impairment in Multiple Sclerosis. Folia Med (Plovdiv). 2016; 58(3):157-163. doi: 10.1515/folmed-2016-0029.
    5. Sumowski JF, Benedict R, Enzinger C, et al. Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology. 2018; 90(6):278–288. doi:10.1212/WNL.0000000000004977
    6. Mehri A, Ghorbani A, Darzi A, Jalaie S, Ashayeri H. Comparing the production of complex sentences in Persian patients with post-stroke aphasia and non-damaged people with normal speaking. Iran J Neurol. 2016; 15(1):28–33.
    7. Migliore S, Ghazaryan A, Simonelli I, et al. Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability. Behav Neurol. 2017; 2017:7404289. doi:10.1155/2017/7404289
    8.  Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler 2013; 19:1765–72.10.1177/1352458513485981
    9. Rouleau I, Dagenais E, Tremblay A, Demers M, Roger E, Jobin C, et al. Prospective memory impairment in multiple sclerosis: A review. Clin Neuropsychol. 2018;32(5):922-936. doi: 10.1080/13854046.2017.1361473.
    10. Shafiee-Kandjani AR, Amiri Sh, Mousavi Z,  Hashemilar M ,  Safikhanlou S ,  Abdi S , Khalili M.  cognitive function in hospitalized Patients with Multiple Sclerosis: A case-CONTROL STUDY. Archives of Neuroscience 2019; 6 (3); e89632
    11. Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological Assessment. 5th Ed. New York: Oxford University Press; 2012. pp. 290-303
    12. Johnen A, Landmeyer NC, Burkner PC, Wiendl H, Meuth SG, Holling H. Distinct cognitive impairments in different disease courses of multiple sclerosis-A systematic review and meta-analysis. Neurosci Biobehav Rev. 2017;83:568-78. doi: 10.1016/j.neubiorev
    13. Ntoskou K, Messinis L, Nasios G, et al. Cognitive and Language Deficits in Multiple Sclerosis: Comparison of Relapsing Remitting and Secondary Progressive Subtypes. Open Neurol J. 2018; 12:19–30. doi:10.2174/1874205X01812010019
    14. Messinis L, Kosmidis MH, Vlahou C, Malegiannaki A, Gatzounis G, Dimisianos N, Karra A, Gourzis P. Papathanasopoulos. Phonological fluency strategy of switching differentiates Relapsing Remitting and Secondary Progressive Multiple Sclerosis Patients. ISRN Neurol. 2013 doi: 10.1155/2013/451429. 
    15. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. doi:10.1002/ana.22366
    16. Nilipour R, Pour Shahbaz A, Ghoreishi Z S, Yousefi A. Reliability and Validity of Persian Aphasia Battery Test. Salmand: Iranian Journal of Ageing. 2016; 10 (4):182-191.
    17. Kertesz A. Aphasia and Associated Disorders: Taxonomy, Localization, and Recovery. New York: Grune & Stratton; 1979.
    18. Kertesz A. Western Aphasia Battery- Revised (WAB-R): Examiner’s Manual. PsychCorp. Harcort Assessment Incorporation, 2006.
    19.  Feenaughty L, Tjaden K, Benedict RH, Weinstock-Guttman B. Speech and pause characteristics in multiple sclerosis: a preliminary study of speakers with high and low neuropsychological test performance. Clin Linguist Phon. 2013;27(2):134–151. doi:10.3109/02699206.2012.751624
    20. Rodgers JD, Tjaden K, Feenaughty L, Weinstock-Guttman B, Benedict RH. Influence of cognitive function on speech and articulation rate in multiple sclerosis. J Int Neuropsychol Soc. 2013;19(2):173–180. doi:10.1017/S1355617712001166
    21. Kambanaros M, Messinis L, Nasios G, Nousia A, Papathanasopoulos P. Verb noun dissociations in relapsing remitting multiple sclerosis: Verb effects of semantic complexity and phonological relatedness. Aphasiology. 2017; 31:49–66. doi: 10.1080/02687038.2016.1154498.
    22. Messinis L, Kosmidis MH, Lyros E, Papathanasopoulos P. Assessment and rehabilitation of cognitive impairment in multiple sclerosis. International Review of Psychiatry. 2010; 22:22-34
    23. Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, Petersen RC. Classifying neurocognitive disorders: The DSM-5 approach. Nat. Rev. Neurol. 2014; 10:634–642. doi: 10.1038/nrneurol.2014.181. 
    24. Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Mult Scler. 2008;14(9):1250–1261. doi:10.1177/1352458508095004
    25. Noffs GPerera TKolbe SCShanahan CJBoonstra FMCEvans AButzkueven Hvan der Walt AVogel AP.What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis. Autoimmun  2018; 17(12):1202-1209. doi: 10.1016/j.autrev.2018.06.010.
    26. Friedova LRusz JMotyl JSrpova BVodehnalova KAndelova MNovotna KNovotny MRuzickova HTykalova TKubala Havrdova EHorakova DUher T. Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. J Clin Neurosci. 2019; 65:28-33. doi: 10.1016/j.jocn.2019.04.018.
    27. Dehnavi S, Hashemi  S, Zadeh-Mohammadi  A. The effectiveness of psychodrama on reducing depression among multiple sclerosis patients. International Journal of Behavioral Sciences, 2016; 9(4): 32-35.
    28. Nazarboland  N, Tehranizadeh M, Mozaffarinejad  F. Effectiveness of Cognitive Behavioral Therapy for Multiple Sclerosis (MS) Fatigue. International Journal of Behavioral Sciences, 2017; 10(4): 19-24.